Study Of Abraxane® And Carboplatin As First-Line Treatment For Triple Negative Metastatic Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Abraxane|DRUG: Carboplatin
Sponsor: Duke University
Collaborators: Celgene Corporation